To decide Recommended dose of XELIRI and bevacizumab in patients with metastatic colorectal cancer who have oxlplatin based first-line chemotherapy including treatment failure or refractory, and To evaluate the safety and efficacy -PhaseI/II Study
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2017 Results published in the Cancer Chemotherapy and Pharmacology
- 24 Jun 2017 Status changed from active, no longer recruiting to completed.
- 04 Feb 2012 New trial record